Dominic Pauly1, Sonja Hamed1, Michael Behnes1, Dominic Lepiorz1, Siegfried Lang1, Ibrahim Akin1, Martin Borggrefe1, Thomas Bertsch2, Ursula Hoffmann3. 1. First Department of Medicine, University Medical Centre Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany. 2. Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany. 3. First Department of Medicine, University Medical Centre Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany. Electronic address: Ursula.Hoffmann@umm.de.
Abstract
PURPOSE: This study aims to assess the diagnostic and prognostic value of endocan in patients with severe sepsis or septic shock on a medical intensive care unit (ICU). METHODS: 150 patients suspected for at least severe sepsis were enrolled on a medical ICU. On days 1, 3, and 8, plasma levels of endocan, procalcitonin (PCT), and interleukin (IL)-6 were measured. Follow-up on all-cause mortality was performed after 30 days and 6 months. RESULTS: Endocan correlated with Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology Score II (SAPS II) (P < .006). Endocan was higher in patients with at least severe sepsis compared with systemic inflammatory response syndrome (SIRS) or sepsis patients (P = .0006) on days 1, 3, and 8. With a minimum sensitivity of 70%, uniform cutoff levels were set for ≥ sepsis at 1.8 ng/mL, for ≥ severe sepsis at 2.6 ng/mL, for ≥ septic shock at 2.9 ng/mL. On day 1, endocan levels of the fourth quartile were significantly associated with 30-days and 6-months mortality compared to lower levels. After adjustment in Cox regressions, endocan still revealed prognostic value. CONCLUSIONS: Endocan showed diagnostic capacity to diagnose patients with severe sepsis and septic shock and revealed prognostic information for 30-days and 6-months all-cause mortality.
PURPOSE: This study aims to assess the diagnostic and prognostic value of endocan in patients with severe sepsis or septic shock on a medical intensive care unit (ICU). METHODS: 150 patients suspected for at least severe sepsis were enrolled on a medical ICU. On days 1, 3, and 8, plasma levels of endocan, procalcitonin (PCT), and interleukin (IL)-6 were measured. Follow-up on all-cause mortality was performed after 30 days and 6 months. RESULTS: Endocan correlated with Acute Physiology and Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment (SOFA), and Simplified Acute Physiology Score II (SAPS II) (P < .006). Endocan was higher in patients with at least severe sepsis compared with systemic inflammatory response syndrome (SIRS) or sepsispatients (P = .0006) on days 1, 3, and 8. With a minimum sensitivity of 70%, uniform cutoff levels were set for ≥ sepsis at 1.8 ng/mL, for ≥ severe sepsis at 2.6 ng/mL, for ≥ septic shock at 2.9 ng/mL. On day 1, endocan levels of the fourth quartile were significantly associated with 30-days and 6-months mortality compared to lower levels. After adjustment in Cox regressions, endocan still revealed prognostic value. CONCLUSIONS: Endocan showed diagnostic capacity to diagnose patients with severe sepsis and septic shock and revealed prognostic information for 30-days and 6-months all-cause mortality.
Authors: Daniel Molano Franco; Ingrid Arevalo-Rodriguez; Marta Roqué I Figuls; Nadia G Montero Oleas; Xavier Nuvials; Javier Zamora Journal: Cochrane Database Syst Rev Date: 2019-04-30
Authors: Jane E Whitney; Binqing Zhang; Natalka Koterba; Fang Chen; Jenny Bush; Kathryn Graham; Simon F Lacey; Jan Joseph Melenhorst; David T Teachey; Janell L Mensinger; Nadir Yehya; Scott L Weiss Journal: Crit Care Med Date: 2020-03 Impact factor: 7.598
Authors: Yu Ho Lee; Jin Sug Kim; Se-Yun Kim; Yang Gyun Kim; Ju-Young Moon; Kyung-Hwan Jeong; Tae Won Lee; Chun-Gyoo Ihm; Sang-Ho Lee Journal: Kidney Res Clin Pract Date: 2016-07-14
Authors: Nathalie De Freitas Caires; Alexandre Gaudet; Lucie Portier; Anne Tsicopoulos; Daniel Mathieu; Philippe Lassalle Journal: Crit Care Date: 2018-10-26 Impact factor: 9.097